genetic effectsとは 意味・読み方・使い方

The marker group for predicting therapeutic effects on hepatitis C includes the first marker, which is an oligonucleotide or polynucleotide including genetic polymorphism rs8099917, and at least one oligonucleotide or polynucleotide selected from genetic polymorphism rs2076954, rs12907066, rs9528038 and rs341554 as another marker.例文帳に追加

第一のマーカーは、遺伝子多型のうちrs8099917を含むオリゴヌクレオチド又はポリヌクレオチドであり、さらにrs2076954, rs12907066, rs9528038及びrs341554から選択されるいずれかを含むオリゴヌクレオチド又はポリヌクレオチドを他のマーカーとして少なくとも１種含むことを特徴とする、Ｃ型肝炎の治療効果を予測するためのマーカー群による。 - 特許庁

(3)Where a patent concerns a product consisting of or containing genetic information as a result of an invention, the effects of Section 9 shall extend to any material in which the product is incorporated and in which the genetic information is contained and performs its function. Section 1a(1) shall not be effected thereby. Should the patentee or a third party with the consent of patentee put biological material possessing certain characteristics owing to the invention on the market within the territory of a Member State of the European Union or in a contracting state of the European Economic Area Agreement and should further biological material be produced from this biological material by multiplication or propagation, the effects of Section 9 shall not come into force if the propagation of the biological material was the reason why this was put on the market. This shall not apply if the material produced by this means is used thereafter for a further multiplication or propagation.発音を聞く 例文帳に追加

(3) 特許が，発明の結果として遺伝子情報から成り，又はそれを含有している製品に関するものである場合は，第 9条の効力は，その製品が組み込まれており，遺伝子情報が包含されており，また，その機能を果たす全ての材料に及ぶものとする。 - 特許庁

(3)Where a patent concerns a product consisting of or containing genetic information as a result of an invention, the effects of Section 9 shall extend to any material in which the product is incorporated and in which the genetic information is contained and performs its function. Section 1a(1) shall not be effected thereby. Should the patentee or a third party with the consent of patentee put biological material possessing certain characteristics owing to the invention on the market within the territory of a Member State of the European Union or in a contracting state of the European Economic Area Agreement and should further biological material be produced from this biological material by multiplication or propagation, the effects of Section 9 shall not come into force if the propagation of the biological material was the reason why this was put on the market. This shall not apply if the material produced by this means is used thereafter for a further multiplication or propagation.発音を聞く 例文帳に追加

(3) 特許が，発明の結果として遺伝子情報から成り，又はそれを含有している製品に関するものである場合は，第 9条の効力は，その製品が組み込まれており，遺伝子情報が包含されており，また，その機能を果たす全ての材料に及ぶものとする。第 1a条(1)は，この規定によっては影響を受けない。 - 特許庁

To provide a method for determining occurrence risk of adverse effects of irinotecan which detects genetic polymorphism in a TATA box in the promoter region of glucuronosyltransferase (UGT) gene in high precision and obtains a determined result with high reliability.例文帳に追加

グルクロン酸抱合酵素遺伝子（UGT）遺伝子のプロモーター領域TATAボックスにおける遺伝子多型を高確度に検出して、信頼性の高い判定結果を得ることが可能なイリノテカンの副作用発生危険度の判定方法の提供。 - 特許庁

To eliminate effects of a background noise with an inserting agent nonspecifically adsorbed on a single-stranded nucleic acid probe or electrode surfaces in relation to a method for detecting a gene comprising detecting a specific genetic sequence with the inserting agent.例文帳に追加

特定の遺伝子配列を、挿入剤を用いて検出する遺伝子検出方法に関し、１本鎖の核酸プローブや電極表面に非特異的に吸着する挿入剤によるバックグランドノイズの影響を無くする。 - 特許庁

As to "How Specifically Must the Detailed Description of the Invention Be Described?", "Balance of the Claim and the Detailed Description of the Invention," "Ministerial Ordinance Requirement" and "Prior Art and Advantageous Effects," see the relevant portions (1.1.2.1 (4) and (5), 1.1.2.2 and 1.1.2.3) in "1. Genetic Engineering."発音を聞く 例文帳に追加

なお、「説明の具体化の程度について」、「請求項の記載と発明の詳細な説明との関係」、「委任省令要件」、「従来技術及び有利な効果について」については、「 1.遺伝子工学」の該当箇所(1.1.2.1 (4)及び(5)、1.1.2.2及び 1.1.2.3) を参照。 - 特許庁

As to "How Specifically Must the Detailed Description of the Invention Be Described?", "Balance of the Claim and the Detailed Description of the Invention," "Ministerial Ordinance Requirement" and "Prior Art and Advantageous Effects," see the relevant portions (1.1.2.1 (4) and (5), 1.1.2.2 and 1.1.2.3) in "1. Genetic Engineering."発音を聞く 例文帳に追加

なお、「説明の具体化の程度について」、「請求項の記載と発明の詳細な説明との関係」、「委任省令要件」、「従来技術及び有利な効果について」については、「1.遺伝子工学」の該当箇所(1.1.2.1(4)及び(5)、1.1.2.2及び1.1.2.3)を参照。 - 特許庁

a certain amount of normal (polymorphic) variation in repeat number with no clinical significance commonly occurs between individuals; however, repeat numbers over a certain threshold can, in some cases, lead to adverse effects on the function of the gene, resulting in genetic disease.発音を聞く 例文帳に追加

臨床的意義のない反復数のある程度の正常な（多型性の）ばらつきは、人によって普通に発生するが、ある域値を超える反復数は、時として遺伝子機能に有害作用を及ぼして遺伝性疾患を引き起こすことがある。 - PDQ®がん用語辞書 英語版